Business Wire

AI Won't Transform Mobility Without Unprecedented Collaboration, Study Reveals

8.12.2025 10:25:00 EET | Business Wire | Press release

Share

Artificial intelligence is quietly reshaping global transportation systems, but most deployments remain isolated pilots that haven't achieved scale – and the gap between AI's promise and its execution is widening, according to a landmark study launched today at CoMotion GLOBAL in Riyadh.

The Envisioning the Future of Mobility Powered by AI report, developed by the MIT Mobility Initiative and Kearney Advanced Mobility Institute, analyzed input from 55 leading global organizations, including Google, Lyft, Uber Freight, Deutsche Bahn, and NEOM. The study mapped real-world AI applications across mobility systems in Europe, the Americas, APAC, and the Middle East – revealing both breakthrough potential and fundamental challenges in bringing AI-powered mobility to scale.

The report identifies a critical dynamic reshaping the industry: AI doesn't simply replicate human intelligence – it excels dramatically in some functions while failing unpredictably in others. This "jagged frontier" creates both opportunity and risk in safety-critical transportation systems.

"The industry sees enormous opportunity – but also fragmentation," said John Moavenzadeh, Executive Director of the MIT Mobility Initiative. "Our study reveals a paradox: the bigger the potential for AI to deliver safe, clean, and inclusive mobility, the tougher the execution becomes. Delivering on this promise will require governments, regulators, operators, and technology leaders to collaborate across borders and share a common vision of impact, safety, and trust."

Key Findings

  • AI adoption remains fragmented: Most applications across network planning, autonomous driving, demand simulation, and crowd monitoring are pilots, not scaled systems
  • System-level coordination delivers exponential value: AI's potential increases dramatically when deployed across entire systems – optimizing fleets, infrastructure, energy use, and passenger flows simultaneously – but requires unprecedented public-private cooperation
  • Human-AI pairing is safety-critical: In some applications, combining AI with human operators makes systems safer. In others, human intervention actually reduces reliability. Understanding this balance is now a strategic imperative
  • The execution gap is widening: Without shared data infrastructure, interoperable standards, and coherent governance frameworks, regions risk fragmenting into competing and potentially incompatible AI futures

The study confirms that many of the highest-impact applications – including autonomous fleets, adaptive traffic control, and automated enforcement – sit closest to the jagged frontier.

"Cities are waking up to the reality that AI isn't just a smarter algorithm – it changes how humans and machines share control," said Dr. Christian Gasparic, Partner at Kearney and Global Head of the Kearney Advanced Mobility Institute. "Getting that balance right is now a strategic, safety-critical decision that will define which cities succeed in building the next generation of mobility systems."

Kristin White, Head of Transportation Strategy and Partnerships at Google Public Sector, who contributed to the report, added: “Public mission and placing humans at the center of problem solving is critical for AI to be successful, to scale, and to achieve a safer and more resilient transportation system.”

“AI is already supporting our agenda of satisfied customers by providing safe, reliable and clean railway and bus services in Germany and beyond, and this study shows its greatest value comes when solutions scale across entire mobility systems," said Dr. Axel Sondermann, Executive Director at Deutsche Bahn. "But unlocking AI’s full potential will require shared standards and collaboration across the industry. We’re committed to that collective effort to create better, more resilient mobility for all.”

The report warns that progress now depends less on isolated innovation and more on ecosystem execution. Without coordination among public agencies, private operators, and technology providers, the promise of AI-powered mobility – safer streets, cleaner air, and more equitable access – may remain unrealized.

"We are proud to launch this unprecedented research on Artificial Intelligence at CoMotion GLOBAL in Riyadh," said John Rossant, Founder & CEO of CoMotion. "If the world wants clean, inclusive, and safe transportation systems, the next leap won't come from individual breakthroughs; it will come from collaboration. Our role is to bring governments, operators, technologists, and cities together so this future can be built, not just imagined."

About CoMotion

CoMotion is the world’s leading platform where the most influential leaders, companies, startups, and policymakers meet to shape the future of mobility. With flagship events in Riyadh, Los Angeles, and Miami, CoMotion fosters meaningful dialogue and catalyzes investments that advance sustainable and equitable transportation worldwide.

For more information, visit www.comotionglobal.com.

About Kearney Advanced Mobility Institute

Kearney Advanced Mobility Institute (KAMI) is part of Kearney’s Foresight network, helping companies, governments, and nonprofits implement innovative mobility solutions. They work across the entire mobility ecosystem to modernize and improve transportation with a uniquely data-driven approach.

About MIT Mobility Initiative

The MIT Mobility Initiative brings together departments and institutions across MIT in a global platform to accelerate the development of safe, clean, and inclusive mobility systems.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251207251103/en/

Contacts

Media Contact:
Kristin Ford-Glencross
comotion@antennagroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye